Paradoxical tralokinumab-induced psoriasis in a patient with atopic dermatitis

Conclusions: This case suggests, that not only a dual IL-4-/IL-13-blockade, but also a selective IL-13-inhibition is able to skew immune responses toward IL-17 cytokine pathway-related disease. However, no clinical scores exist to predict the development of paradoxical psoriasis in patients with AD during therapy with biologics.PMID:37705378 | DOI:10.1080/09546634.2023.2258240
Source: Journal of Dermatological Treatment - Category: Dermatology Authors: Source Type: research